Associate Medical Director, Prostate Cancer Theranostics
- Market p25–p75
- $171k–$260k
- Opened · 30d
- +0
- Closed · 30d
- −0
- Opened · 7d
- +1,5216% of open
- All other
- 623,313open
Telix Pharmaceuticals is a dynamic, fast-growing radiopharmaceutical company with offices in Australia (HQ), Belgium, Japan, Switzerland, and the United States. Our mission is to deliver on the promise of precision medicine through targeted radiation. At our core, we exist to create products that seek to improve the quality of life for people living with cancer and rare diseases. You will be supporting the international roll-out of our approved prostate cancer imaging agent and helping us to advance our portfolio of late clinical-stage products that address significant unmet need in oncology and rare diseases.
See Yourself at Telix
The Associate Medical Director, Prostate Cancer Theranostics leads the execution of the US medical affairs plan across the prostate cancer theranostic portfolio, contributing to medical strategy, launch readiness, and lifecycle planning in partnership with the VP of Medical Affairs Americas. The role drives alignment of medical deliverables across Commercial, Clinical Operations, Marketing, Market Access, HEOR, Regulatory, Development, and other Medical Affairs partners. The Associate Medical Director develops and delivers core components of the medical plan, including medical education, advisory boards, podium and speaker content, investigator-initiated trial (IIT) strategy, clinical trial recruitment support, and scientific communications. As a subject-matter expert in prostate cancer radiopharmaceuticals and the prostate cancer patient journey, the role maintains current knowledge of publications, clinical trials, guidelines, and standards of care, and translates emerging data into recommendations for medical leadership.
Key Accountabilities
- Lead execution of the US medical affairs plan for the prostate cancer theranostic portfolio, contributing to medical strategy, priorities, and the medical operating plan in partnership with the VP of Medical Affairs Americas.
- Drive cross-functional alignment with US Medical Affairs, Clinical Development, Commercial, Market Access, HEOR, Regulatory, Marketing, and Medical Information on medical deliverables and timelines.
- Contribute to medical affairs strategy for prostate cancer theranostic assets, including launch readiness and lifecycle planning, and lead integration of medical tactics and deliverables.
- Serve as a subject-matter expert on prostate cancer theranostics, providing scientific input into integrated medical planning, evidence gaps, and competitive landscape.
- Provide medical leadership on prostate cancer clinical protocol review, including recruitment strategy, data interpretation, investigator engagement, expanded access programs, clinical registries, and IIT protocol review.
- Develop and review scientifically accurate medical content, including podium presentation materials, speaker decks, medical education programs, advisory board content, symposia materials, and promotional/non-promotional resources through MLR review.
- Prepare and support internal and external speakers, ensuring scientific narrative, clinical context, competitive landscape, and use of data are clear, balanced, compliant, and aligned to medical strategy.
- Build and maintain scientific relationships with KOLs, investigators, and professional societies in prostate cancer theranostics.
Maintain current knowledge of prostate cancer radiopharmaceutical publications, clinical trials, treatment guidelines, patient journey dynamics, and competitive data, and translate implications into recommendations for medical leadership.
Education and Experience
- Advanced degree (PhD, PharmD, MD) with prostate oncology experience required or equivalent experience.
- 8+ years of Medical Affairs experience, including experience leading cross-functional initiatives in oncology or specialty therapeutics
- Experience working with clinical operations, R&D and/or medical affairs.
- Deep expertise in prostate cancer radiopharmaceuticals, theranostics, imaging and therapy integration, and the prostate cancer patient journey preferred.